An Exome-Based Model to Predict Benefit of ICIs in NSCLC

Currently used assays that gauge potential response to immune checkpoint inhibitors have limited predictive value, noted researchers.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2GozaPG